Latest Insider Transactions at Kronos Bio, Inc. (KRON)
This section provides a real-time view of insider transactions for Kronos Bio, Inc. (KRON). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kronos Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kronos Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
204,670
+1.86%
|
$204,670
$1.25 P/Share
|
|
Jun 27
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
410,848
+3.73%
|
$410,848
$1.17 P/Share
|
|
Jun 25
2024
|
Elena Ridloff |
BUY
Grant, award, or other acquisition
|
Direct |
11,333
+30.94%
|
-
|
|
Jun 12
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
881,913
+10.68%
|
$881,913
$1.24 P/Share
|
|
Jun 11
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
744,308
+10.28%
|
$744,308
$1.09 P/Share
|
|
Jun 10
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
1,378,901
+19.34%
|
$0
$0.88 P/Share
|
|
Jun 03
2024
|
Deborah Knobelman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
164,260
+50.0%
|
-
|
|
Feb 21
2024
|
Elizabeth A Olek SR VP, CLINICAL SCIENCE |
SELL
Open market or private sale
|
Direct |
7,368
-3.67%
|
$7,368
$1.05 P/Share
|
|
Feb 21
2024
|
Allison Frisbee SR VP, CORP OPERATIONS & LEGAL |
SELL
Open market or private sale
|
Direct |
12,105
-5.59%
|
$12,105
$1.05 P/Share
|
|
Feb 21
2024
|
Charles Y Lin SR VP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
12,036
-4.88%
|
$12,036
$1.05 P/Share
|
|
Feb 15
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
270,339
+8.77%
|
-
|
|
Jan 04
2024
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,366
-2.75%
|
$7,366
$1.18 P/Share
|
|
Jan 04
2024
|
Barbara Kosacz COO & General Counsel |
SELL
Open market or private sale
|
Direct |
10,676
-1.14%
|
$10,676
$1.18 P/Share
|
|
Jan 04
2024
|
Jorge Di Martino Chief Medical Officer & VP |
SELL
Open market or private sale
|
Direct |
12,009
-3.67%
|
$12,009
$1.18 P/Share
|
|
Dec 12
2023
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,032
-3.6%
|
$10,032
$1.3 P/Share
|
|
Dec 12
2023
|
Jorge Di Martino Chief Medical Officer & VP |
SELL
Open market or private sale
|
Direct |
17,367
-5.04%
|
$17,367
$1.3 P/Share
|
|
Nov 17
2023
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
97,935
+3.71%
|
$97,935
$1.08 P/Share
|
|
Nov 16
2023
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
262,433
+9.7%
|
$262,433
$1.0 P/Share
|
|
Nov 15
2023
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
1,370,688
+38.6%
|
$0
$0.8 P/Share
|
|
Jul 06
2023
|
Yasir B. Al Wakeel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,617
-2.7%
|
$9,617
$1.75 P/Share
|
|
Jul 06
2023
|
Jorge Di Martino Chief Medical Officer & VP |
SELL
Open market or private sale
|
Direct |
10,818
-3.04%
|
$10,818
$1.75 P/Share
|
|
Jul 06
2023
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,634
-2.33%
|
$6,634
$1.75 P/Share
|
|
Jun 22
2023
|
Elena Ridloff |
BUY
Grant, award, or other acquisition
|
Direct |
11,333
+44.8%
|
-
|
|
Feb 24
2023
|
Yasir B. Al Wakeel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,026
-2.47%
|
$9,026
$1.74 P/Share
|
|
Feb 24
2023
|
Jorge Di Martino Chief Medical Officer & VP |
SELL
Open market or private sale
|
Direct |
10,153
-2.78%
|
$10,153
$1.74 P/Share
|
|
Feb 24
2023
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,291
-2.16%
|
$6,291
$1.74 P/Share
|
|
Feb 15
2023
|
Jorge Di Martino Chief Medical Officer & VP |
BUY
Grant, award, or other acquisition
|
Direct |
137,008
+27.26%
|
-
|
|
Feb 15
2023
|
Barbara Kosacz COO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
138,911
+12.88%
|
-
|
|
Feb 15
2023
|
Christopher Dinsmore Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
119,882
+29.16%
|
-
|
|
Feb 15
2023
|
Yasir B. Al Wakeel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
138,911
+27.58%
|
-
|
|
Dec 12
2022
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,138
-5.31%
|
$9,138
$1.81 P/Share
|
|
Dec 12
2022
|
Jorge Di Martino Chief Medical Officer & VP |
SELL
Open market or private sale
|
Direct |
18,657
-7.83%
|
$18,657
$1.81 P/Share
|
|
Jul 25
2022
|
Christopher Dinsmore Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,550
+20.2%
|
-
|
|
Jul 25
2022
|
Jorge Di Martino Chief Medical Officer & VP |
BUY
Grant, award, or other acquisition
|
Direct |
60,300
+20.21%
|
-
|
|
Jul 25
2022
|
Yasir B. Al Wakeel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,600
+19.82%
|
-
|
|
Jul 25
2022
|
Barbara Kosacz COO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
53,600
+6.34%
|
-
|
|
Jun 22
2022
|
Marianne De Backer Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,333
+44.59%
|
-
|
|
Jun 22
2022
|
Taiyin Yang |
BUY
Grant, award, or other acquisition
|
Direct |
11,333
+50.0%
|
-
|
|
May 19
2022
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
300,000
+27.04%
|
$900,000
$3.78 P/Share
|
|
May 18
2022
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
206,198
+28.81%
|
$618,594
$3.72 P/Share
|
|
May 17
2022
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
90,931
+23.06%
|
$272,793
$3.83 P/Share
|
|
Mar 07
2022
|
Joshua A Kazam |
SELL
Bona fide gift
|
Direct |
211,000
-69.07%
|
-
|
|
Mar 07
2022
|
Joshua A Kazam |
BUY
Bona fide gift
|
Direct |
211,000
+40.85%
|
-
|
|
Feb 15
2022
|
Yasir B. Al Wakeel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,600
+24.72%
|
-
|
|
Feb 15
2022
|
Christopher Dinsmore Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,550
+25.31%
|
-
|
|
Feb 15
2022
|
Jorge Di Martino Chief Medical Officer & VP |
BUY
Grant, award, or other acquisition
|
Direct |
60,300
+25.32%
|
-
|
|
Feb 15
2022
|
Barbara Kosacz COO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
53,600
+6.77%
|
-
|
|
Dec 13
2021
|
Jorge Di Martino Chief Medical Officer & VP |
SELL
Open market or private sale
|
Direct |
16,402
-6.14%
|
$196,824
$12.59 P/Share
|
|
Dec 13
2021
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,386
-5.92%
|
$136,632
$12.59 P/Share
|
|
Dec 06
2021
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
14,356
+6.33%
|
$172,272
$12.09 P/Share
|